Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other Events
Item8.01 Other Events.
On May9, 2017, Recro Pharma, Inc. (the Company) issued a press
release announcing successful top-line results from its Phase III
safety study evaluating intravenous (IV)meloxicam (30mg bolus
injection) following major surgery. A copy of the press release
is filed as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Document |
|
| 99.1 | Press release of Recro Pharma, Inc., dated May9, 2017. |
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients. Recro Pharma, Inc. (NASDAQ:REPH) Recent Trading Information
Recro Pharma, Inc. (NASDAQ:REPH) closed its last trading session up +0.02 at 7.51 with 51,994 shares trading hands.
